RSV基因組大小約15~16 kb，編碼11種蛋白，包括8種結(jié)構(gòu)蛋白和3種非結(jié)構(gòu)蛋白(NS1、NS2和M2-2)，結(jié)構(gòu)蛋白包括3種跨膜表面蛋白(G、F、SH)、2種基質(zhì)蛋白(M和M2-1)、3種核殼蛋白(L、N和P)。

貨號：DVV02822

產(chǎn)品鏈接：http://www.antibodysystem.com/product/9575.html

物種反應(yīng)性：Human respiratory syncytial virus A (strain A2)

形式：Liquid

存儲緩沖區(qū)：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95% by SDS-PAGE.

克隆性：Monoclonal

應(yīng)用：Research Grade Biosimilar

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻：

?

RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. PMID: 36535957
Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein. PMID: 30769923
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. PMID: 27682426
Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring. PMID: 32197348
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. PMID: 32045432
The Optimal Concentration of Formaldehyde is Key to Stabilizing the Pre-Fusion Conformation of Respiratory Syncytial Virus Fusion Protein. PMID: 31288455
The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV. PMID: 28604155
Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. PMID: 31623333

呼吸道合胞病毒(respiratory syncytial virus，RSV)感染是一個全球性的健康問題，目前臨床上仍缺乏特異的治療手段。接種疫苗主動免疫預(yù)防或使用抗體制劑被動免疫預(yù)防是避免重癥感染和減少死亡的重要措施。針對不同的人群，須研制不同類型的RSV疫苗：減毒活疫苗對嬰兒來說，可能是最佳選擇；亞單位疫苗有引起增強型呼吸道疾病的風(fēng)險，不適合RSV血清學(xué)陰性的嬰幼兒接種，主要適用于老年人和孕婦。研發(fā)安全且有效的RSV疫苗難度大，雖然已有30余種RSV疫苗進入臨床研究階段，并顯示出應(yīng)用潛力，其中F納米顆粒疫苗已率先進入Ⅲ期臨床試驗，但在老年人和孕婦中未達預(yù)期效果。在RSV流行季節(jié)前，使用特異性抗體制劑也是預(yù)防高危人群嚴(yán)重RSV感染性疾病的有效手段。長效單克隆抗體MEDI8897比帕利珠單抗更具成本效益，已進入Ⅲ期臨床試驗，且獲得優(yōu)先研發(fā)資格。多克隆免疫球蛋白RI-002已在免疫缺陷人群中顯示出較好的預(yù)防效果，具有進一步研發(fā)的現(xiàn)實意義。